In summary, these studies further highlight YB‐1 as a potent metastatic driver in high‐risk childhood bone sarcomas by enhancing tumor cell fitness during the metastatic cascade, including through an elevated NRF2‐mediated antioxidant response. The gene discussed is NFE2L2; the disease is bone sarcoma.